1. Academic Validation
  2. Harnessing free energy calculations for kinome-wide selectivity in drug discovery campaigns with a Wee1 case study

Harnessing free energy calculations for kinome-wide selectivity in drug discovery campaigns with a Wee1 case study

  • Nat Commun. 2025 Aug 26;16(1):7962. doi: 10.1038/s41467-025-62722-w.
Jennifer Lynn Knight 1 Anthony J Clark 2 Jiashi Wang 2 Andrew Placzek 3 Pieter H Bos 2 Sathesh Bhat 2 Jeffrey A Bell 2 Sarah Silvergleid 2 Wu Yin 2 Felicia Gray 3 Shaoxian Sun 2 Karen Akinsanya 2 Robert Abel 2 Aleksey I Gerasyuto 4
Affiliations

Affiliations

  • 1 Schrödinger, Inc., New York, NY, USA. jennifer.knight@schrodinger.com.
  • 2 Schrödinger, Inc., New York, NY, USA.
  • 3 Schrödinger, Inc., Portland, OR, USA.
  • 4 Schrödinger, Inc., New York, NY, USA. aleksey.gerasyuto@schrodinger.com.
Abstract

Optimizing both on-target and off-target potencies is essential for developing effective and selective small-molecule therapeutics. Free energy calculations offer rapid potency predictions, usually within hours and with experimental accuracy and thus enables efficient identification of promising compounds for synthesis, accelerating early-stage drug discovery campaigns. While free energy predictions are routinely applied to individual proteins, here, we present a free energy framework for efficiently achieving kinome-wide selectivity that led to the discovery of selective Wee1 kinase inhibitors. Ligand-based relative binding free energy calculations rapidly identified multiple novel potent chemical scaffolds. Subsequent protein residue mutation free energy calculations that modified the Wee1 gatekeeper residue, significantly reduced their off-target liabilities across the kinome. Thus, with judicious use of this gatekeeper residue selectivity handle, applying this computational strategy streamlined the optimization of both on-target and off-target potencies, offering a roadmap to expedite drug discovery timelines by decreasing unanticipated off-target toxicities.

Figures
Products